Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Sunshine Biopharma, Inc. (SBFM : NSDQ)

• Company Description    Sunshine Biopharma Inc. is a pharmaceutical company. It focused on the research, development and commercialization of oncology and antiviral drugs. Sunshine Biopharma Inc. is based in MONTREAL. Number of Employees: 52

• Price / Volume Information    Yesterday's Closing Price: $1.48 Daily Weekly Monthly 20 Day Moving Average: 42,845 shares Shares Outstanding: 4.56 (millions) Market Capitalization: $6.74 (millions) Beta: 1.46 52 Week High: $3.75 52 Week Low: $1.17 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.99% -3.76% 12 Week 0.34% -8.90% Year To Date -50.67% -55.95%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 333 LAS OLAS WAY CU4 SUITE 433 - FORT LAUDERDALE,FL 33301 USA ph: 954-330-0684 fax: - investors@sunshinebiopharma.com https://sunshinebiopharma.com

• General Corporate Information    Officers Steve N. Slilaty - Chief Executive Officer Camille Sebaaly - Chief Financial Officer David Natan - Director Rabi Kiderchah - Director Andrew Keller - Director Peer Information Sunshine Biopharma, Inc. (CORR.) Sunshine Biopharma, Inc. (RSPI) Sunshine Biopharma, Inc. (CGXP) Sunshine Biopharma, Inc. (BGEN) Sunshine Biopharma, Inc. (GTBP) Sunshine Biopharma, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 867781700 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/04/25 Share - Related Items Shares Outstanding: 4.56 Most Recent Split Date: 8.00 (0.05:1) Beta: 1.46 Market Capitalization: $6.74 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/04/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.26 Price/Cash Flow: - Price / Sales: 0.19 EPS Growth vs. Year Ago Period: 96.08% vs. Previous Quarter: 11.36% Sales Growth vs. Year Ago Period: 1.15% vs. Previous Quarter: 5.72% ROE 06/30/25 - -26.04 03/31/25 - -21.25 12/31/24 - -21.22 ROA 06/30/25 - -20.72 03/31/25 - -16.89 12/31/24 - -16.86 Current Ratio 06/30/25 - 5.00 03/31/25 - 4.25 12/31/24 - 4.11 Quick Ratio 06/30/25 - 2.66 03/31/25 - 2.19 12/31/24 - 2.33 Operating Margin 06/30/25 - -17.35 03/31/25 - -13.88 12/31/24 - -14.72 Net Margin 06/30/25 - -17.35 03/31/25 - -13.88 12/31/24 - -14.72 Pre-Tax Margin 06/30/25 - -17.80 03/31/25 - -14.70 12/31/24 - -15.40 Book Value 06/30/25 - 5.63 03/31/25 - 8.38 12/31/24 - 9.10 Inventory Turnover 06/30/25 - 2.11 03/31/25 - 2.43 12/31/24 - 2.60 Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©